资讯

Arcutis Biotherapeutics: A Closer Look At The Atopic Dermatitis Direction
Arcutis is financially strong, with over 30 months of cash runway. The atopic dermatitis market is large and shifting away ...
Yahoo Finance1 年
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
Patent challenge initiated by Arcutis BiotherapeuticsNESS ZIONA, Israel, April 01, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company pioneering treatments ...
WebMD1 年
What Are PDE-4 Inhibitors for Atopic Dermatitis? - WebMD
The FDA has so far approved one topical PDE-4 inhibitor, crisaborole (Eucrisa) for atopic dermatitis. It’s available as an ointment in a 2% concentration. The ointment not only delivers the ...
Managed Healthcare Executive1 年
Vtama Is Getting Ready to Elbow Its Way Into the Crowded Field of Atopic Dermatitis Medications
The company announced earlier this month that it was preparing to file application for supplemental new drug application for Vtama (pronounced vee-TAM-uh) this quarter. That announcement also included ...
Healio1 年
Crisaborole ointment effective as long-term maintenance therapy for atopic dermatitis - Healio
Once-daily crisaborole ointment 2% may be an effective and well-tolerated long-term maintenance therapy for pediatric and adult patients with mild to moderate atopic dermatitis, according to a ...
Too Old to Operate3 年
A Review of Crisaborole Ointment 2% in Mild to Moderate Atopic Dermatitis
Crisaborole ointment 2% (EucrisaTM) is a new anti-inflammatory phosphodiesterase 4 (PDE4) inhibitor that is approved in the United States for the topical treatment of mild to moderate atopic ...
finanzen3 年
Padagis Confirms First-to-File Patent Challenge For Generic Version Of Eucrisa® - finanzen.at
ALLEGAN, Mich., Sept. 28, 2021 /PRNewswire/ -- Padagis announced today that Anacor Pharmaceuticals, Inc initiated patent litigation on September 24, 2021 in the U.S. District Court for the district of ...
Mena FN3 年
Padagis Confirms First-to-File Patent Challenge For Generic Version Of Eucrisa® - MENAFN.COM
ALLEGAN, Mich., Sept. 28, 2021 /PRNewswire/ -- Padagis announced today that Anacor Pharmaceuticals, Inc initiated patent litigation on September 24, ...
Business Insider3 年
Padagis Confirms First-to-File Patent Challenge For Generic Version Of Eucrisa®
ALLEGAN, Mich., Sept. 28, 2021 /PRNewswire/ -- Padagis announced today that Anacor Pharmaceuticals, Inc initiated patent litigation on September 24, 2021 in the U.S. District Court for the ...
The Blast4 年
Link to Facebook - The Blast
Jessica Simpson is worrying fans as a summery and picnic-set photo brings her in promo mode for pharmaceuticals giant Pfizer. The 40-year-old actress, singer, and fashion mogul this week updated her ...
Indiatimes5 年
Strides Pharma gets USFDA nod for generic ointment to treat skin conditions
Strides Pharma Science on Tuesday said it has received US health regulator's approval for its generic version of triamcinolone acetonide ointment used for treatment of various skin conditions.